News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

New Research Collaboration Agreement (RCA) between Prous Institute and the NIH’s National Center for Advancing Translational Sciences

Barcelona, Spain: The Prous Institute for Biomedical Research (PIBR) today announced a collaboration with the National Institute of Health’s National Center for Advancing Translational Sciences (NCATS) to help advance assessing environmental chemical and drug safety. The research goal is to develop and validate quantitative structure – activity relationship (QSAR) models as tools to provide decision support in risk assessment, protecting human health and the environment. The work involves the use of Prous Institute’s Symmetry platform and NCATS’ quantitative High-Throughput Screening (qHTS) data from the Toxicology in the 21st Century (Tox21) program. In addition to validating existing Symmetry models, new models derived from the collaboration will be integrated into the Symmetry platform.

NCATS also will use Symmetry's Global Mechanism of Action model for rapid high-throughput virtual screening of chemical libraries to elucidate the potential mechanisms of action of small molecules. This approach facilitates the identification of off-target mechanistic liabilities as well as drug design and repurposing. Results of this research collaboration will be made available through publications and presentations.  


About Prous Institute for Biomedical Research:

Prous Institute for Biomedical Research is a privately-held research organization. It was founded as a spin-off of Prous Science, the leading scientific information provider (producer of Drugs of the Future, Drug Data Report and the Integrity drug discovery and development portal, amongst others) acquired by Thomson Reuters in 2007. Building on over 50 years of experience creating and managing biomedical knowledge, Prous Institute for Biomedical Research has developed Symmetry, the world’s first integrated predictive platform for drug discovery and safety evaluation.

Prous Institute SymmetrySM integrates computational tools and methods aiming to replicate in silico the processes through which new drugs are discovered, developed and approved. The platform enables new research hypotheses and elucidates the efficacy and safety profile of small molecules through a range of predictive models. Symmetry helps to de-risk and prioritize projects and speed up drug discovery and development, reducing time, costs and attrition rates.